Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial (vol 399, pg 1779, 2022)

被引：0
|
作者：
Delany-Moretlwe, S.
Hughes, J. P.
Bock, P.
机构：
来源：
LANCET | 2022年 / 399卷 / 10337期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1778 / 1778
页数：1
相关论文
共 50 条
  • [21] CUTHIVAC 001: Results from a Phase I Clinical Trial of a Prophylactic Clade B HIV-1 DNA Vaccine Comparing Multiple Routes of Administration
    Haidari, Goli
    Cope, Alethea
    Miller, Aleisha
    Ridgers, Hazel
    Venables, Suzanne
    Yan, Celine
    Reijonen, Kalevi
    Hannaman, Drew
    Spentzou, Aggeliki
    Hayes, Peter
    Bouliotis, George
    Joseph, Sarah
    Combadiere, Behazine
    McCormack, Sheena
    Shattock, Robin J.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 391 - 391
  • [22] PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial
    McCormack, Sheena
    Ramjee, Gita
    Kamali, Anatoli
    Rees, Helen
    Crook, Angela M.
    Gafos, Mitzy
    Jentsch, Ute
    Pool, Robert
    Chisembele, Maureen
    Kapiga, Saidi
    Mutemwa, Richard
    Vallely, Andrew
    Palanee, Thesla
    Sookrajh, Yuki
    Lacey, Charles J.
    Darbyshire, Janet
    Grosskurth, Heiner
    Profy, Albert
    Nunn, Andrew
    Hayes, Richard
    Weber, Jonathan
    [J]. LANCET, 2010, 376 (9749): : 1329 - 1337
  • [23] Once daily oral relugolix combination therapy versus placebo in patients with endometriosisassociated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) (vol 399, pg 2267, 2022)
    Guidice, L. C.
    As-Sanie, S.
    Ferreira, Arjona J. C.
    [J]. LANCET, 2022, 400 (10353): : 660 - 660
  • [24] Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as secondline treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial (vol 399, pg 2294, 2022)
    Kamdar, M.
    Solomon, S. R.
    Arnason, J.
    [J]. LANCET, 2022, 400 (10347): : 160 - 160
  • [25] Treatment naive HIV-1 infected patients respond immunologically when administered HE2000; Results from a phase I/II clinical trial.
    Frincke, J
    Onizuka-Handa, N
    Stickeny, D
    Ahlem, C
    Reading, C
    [J]. ANTIVIRAL RESEARCH, 2000, 46 (01) : A49 - A49
  • [26] Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial (vol 128, pg 4203, 2022)
    不详
    [J]. CANCER, 2023, 129 (05) : 807 - 807
  • [27] Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial (vol 70, pg 515, 2015)
    Walmsley, S.
    Baumgarten, A.
    Berenguer, J.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (01) : E33 - E33
  • [28] Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
    Landovitz, Raphael J.
    Hanscom, Brett S.
    Clement, Meredith E.
    Tran, Ha, V
    Kallas, Esper G.
    Magnus, Manya
    Sued, Omar
    Sanchez, Jorge
    Scott, Hyman
    Eron, Joe J.
    del Rio, Carlos
    Fields, Sheldon D.
    Marzinke, Mark A.
    Eshleman, Susan H.
    Donnell, Deborah
    Spinelli, Matthew A.
    Kofron, Ryan M.
    Berman, Richard
    Piwowar-Manning, Estelle M.
    Richardson, Paul A.
    Sullivan, Philip A.
    Lucas, Jonathan P.
    Anderson, Peter L.
    Hendrix, Craig W.
    Adeyeye, Adeola
    Rooney, James F.
    Rinehart, Alex R.
    Cohen, Myron S.
    Mccauley, Marybeth
    Grinsztejn, Beatriz
    [J]. LANCET HIV, 2023, 10 (12): : E767 - E778
  • [29] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)
    Mignot, E.
    Mayleben, D.
    Fietzeet, I
    [J]. LANCET NEUROLOGY, 2022, 21 (03):
  • [30] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)
    Mignot, E.
    Mayleben, D.
    Fietze, I
    [J]. LANCET NEUROLOGY, 2022, 21 (06): : E6 - E6
12345